# An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease

> **NCT00106314** · PHASE2 · COMPLETED · sponsor: **Inflabloc Pharmaceuticals** · enrollment: 75 (—)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Dehydroepiandrosterone [DHEA]

## Key facts

- **NCT ID:** NCT00106314
- **Lead sponsor:** Inflabloc Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2006-10
- **Target enrollment:** 75 (—)
- **Last updated:** 2007-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00106314

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00106314, "An Efficacy and Safety Evaluation of Inflabloc Cap in the Treatment of Patients With Crohn's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00106314. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*